Cadrenal Therapeutics, Inc. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Cadrenal Therapeutics, Inc. (CVKD) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $740.14 thousand as of 2023-12-31, per its 10-K filed 2024-03-11.
Discontinued › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2024-03-11
- 2023-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $740.14K.
- 2023-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $740.14K.
- 2023-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $740.14K.
- 2023-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $740.14K.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2023-12-31 | $740.14K 10-K · filed 2024-03-11 |
| 2023-09-30 | $740.14K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $740.14K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $740.14K 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |